BioCentury | May 21, 2020
Product Development

Industry is a white knight right now. Don’t throw it away

Biopharma is having a moment. All eyes are on drug, diagnostic and vaccine developers to get us out of this crisis and back to work. Now, companies -- individually and collectively -- must make good...
BioCentury | May 21, 2020

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

Led by veteran biotech entrepreneur Jean-Pierre Sommadossi, Atea believes an antiviral it had been developing to treat HCV has promise to treat COVID-19 in a population that extends beyond hospitalized patients. The company said Wednesday...
BioCentury | May 21, 2020
Politics, Policy & Law

Can the economy be saved by your right to choose COVID testing?

Combined virus and antibody testing is our best opportunity to identify those who can immediately but carefully return to work, and in doing so restart the economy while minimizing the epidemic’s resurgence. We argue that...
BioCentury | May 12, 2020
Product Development

Vaccine prospects for COVID-19: learnings from a 40-year biotech journey that’s still in progress

I have been in biotech research one way or another for over 40 years. This strange time of quarantine and self-isolation during the COVID-19 outbreak has given me time to reflect on how lessons from...
BioCentury | May 8, 2020
Product Development

Getting real about COVID-19 data with Amy Abernethy and Mark McClellan

Responding to COVID-19 is forcing regulators, medical product developers and health systems to get real about real-world data and evidence as they reach for every available tool to learn about the disease and speed the...
BioCentury | May 7, 2020

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

New round pushes Grail’s venture tally over $1.9B Grail Inc. raised $390 million in a series D round, marking the year's largest venture round to date. New backers, including Public Sector Pension Investment Board and...
BioCentury | Apr 30, 2020
Politics, Policy & Law

Time to discuss COVID-19 vaccine allocation priorities, Gates says

As industry, academic groups and governments accelerate the development of COVID-19 vaccines there is a need to come to agreement on the allocation of limited supplies, Bill Gates said Thursday. In a public note , Gates...
BioCentury | Apr 29, 2020

Kurma closes new fund at €160M, triple size of previous fund

Kurma Partners is the latest European life sciences VC to raise a record fund. The French VC announced the final close of Kurma Biofund III at €160 million ($173.4 million), nearly three times the size...
BioCentury | Apr 23, 2020

FDA’s options for staying on track with PDUFA timelines during COVID-19

The COVID-19 pandemic is severely limiting FDA’s ability to conduct in-person pre-approval site inspections, putting the agency’s ability to meet its regulatory timelines at risk. To avoid delays, companies need to prepare to provide all...
BioCentury | Apr 15, 2020
Product Development

Let’s improve molecular diagnostics reimbursement for the sake of public health

Enough is enough already. We could and should have a national system of molecular diagnostic instruments, with networked reporting, to enable the widespread practice of molecular medicine. It’s 2020, and I feel a need to...
Items per page:
1 - 10 of 470